Two Phase 3 trials showed the drug reduced the annualized relapse rate by 35.2% and 31.2% compared with Aubagio. Roche's competing fenebrutinib posted reductions of 51.1% and 58.5%.

Coforge posts 56.5% net-profit rise as record large deals and Encora integration boost revenue and raise FY27 margin guidance.

Blue chip stocks sold off on Friday as investors fretted over rising tensions between Iran and the US and looked ahead to the Fed's rate decision.

Sam Altman’s OpenAI is reportedly wrapping up a fundraising round that would value the company well above $1 trillion as it mulls when to go public.

Dr. Reddy’s Q2 net falls 32% to ₹913 cr amid softer North America generics, declining revenue, and ongoing product relaunch plans.

American Airlines warned airfares are likely to stay elevated even if fuel prices decline, as surging fuel costs drove deeper losses and an updated earnings forecast.

Gold fell to a three-month low on Friday, and was headed for its steepest weekly decline in over four months as higher energy prices fueled inflation concerns and reinforced elevated US rate...

Micron Technology earns a Strong Buy on strong growth, low valuation, and buyback potential. Click to read this updated look at the MU stock's prospects.